quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:35:36·30d
INSIDERFiling
Vir Biotechnology Inc. logo

SEC Form 4 filed by Sabatini Brent

VIR· Vir Biotechnology Inc.
Health Care
Original source

Companies

  • VIR
    Vir Biotechnology Inc.
    Health Care

Recent analyst ratings

  • Feb 24UpdateRaymond James$19.00
  • Sep 3UpdateEvercore ISI$12.00
  • Aug 27UpdateBofA Securities$14.00
  • Jan 29UpdateJP Morgan$9.00
  • Sep 8UpdateBofA Securities$14.00
  • Mar 6UpdateJP Morgan$34.00

Related

  • PR9h
    Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results
  • SEC7d
    SEC Form DEFA14A filed by Vir Biotechnology Inc.
  • SEC7d
    SEC Form DEF 14A filed by Vir Biotechnology Inc.
  • PR7d
    Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer
  • PR10d
    Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
  • SEC13d
    SEC Form 8-K filed by Vir Biotechnology Inc.
  • INSIDER16d
    SEC Form 4 filed by De Backer Marianne
  • INSIDER21d
    SEC Form 4 filed by Sato Vicki L
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022